Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer in Preclinical Tumor Models

PURPOSE: Triple-negative breast cancer (TNBC) is related with a poor prognosis as patients do hardly benefit from approved therapies. CD138 (Syndecan-1) is upregulated on human breast cancers. Indatuximab ravtansine (BT062) is an antibody-drug-conjugate that specifically targets CD138-expressing cel...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Pharm Res
Egile Nagusiak: Schönfeld, Kurt, Herbener, Peter, Zuber, Chantal, Häder, Thomas, Bernöster, Katrin, Uherek, Christoph, Schüttrumpf, Jörg
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer US 2018
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5904230/
https://ncbi.nlm.nih.gov/pubmed/29666962
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11095-018-2400-y
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak